Grace Therapeutics
GRCE
11 hedge funds and large institutions have $778K invested in Grace Therapeutics in 2017 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
22% more funds holding
Funds holding: 9 → 11 (+2)
5% more capital invested
Capital invested by funds: $743K → $778K (+$35.3K)
0% less ownership
Funds ownership: 0.08% → 0.07% (-0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$25.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.35K |
| 3 |
Morgan Stanley
New York
|
+$943 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$7.48K |
| 2 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$126 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PA
1
Perceptive Advisors
New York
| $267K | – | – | – |
|
2
Bank of Montreal
Toronto,
Ontario, Canada
| $248K | – | – | – |
|
|
IIM
3
Intact Investment Management
Montreal,
Quebec, Canada
| $158K | – | – | – |
|
|
4
Citadel Advisors
Miami,
Florida
| $43K | +$7.35K | +117 | +23% |
|
|
5
Renaissance Technologies
New York
| $30K | -$7.48K | -119 | -21% |
|
|
VF
6
Virtu Financial
New York
| $28K | +$25.9K | +412 | New |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $3K | – | – | – |
|
|
8
Morgan Stanley
New York
| $1K | +$943 | +15 | New |
|
|
RE
9
RBC Europe
London,
United Kingdom
| $43 | +$63 | +1 | New |
|
|
10
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$126 | -2 | -50% |
|
GRCE Hedge Fund Activity: Q3 2017 in Review
11 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in Grace Therapeutics (GRCE) for Q3 2017, worth a combined $778K — up 4.7% from $743K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new GRCE positions and 0 closed out — a net gain of 3 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $25.9K. The largest seller was Renaissance Technologies, cutting an estimated $7.48K.
- 11 institutional investors held Grace Therapeutics (GRCE) as of Q3 2017, up from 9 in Q2 2017.
- Funds reported $778K of Grace Therapeutics stock for Q3 2017, up 4.7% quarter-over-quarter.
- 3 funds opened new Grace Therapeutics positions in Q3 2017 and 0 closed out, a net change of +3 holders.
- The largest Grace Therapeutics buyer in Q3 2017 was Virtu Financial, an estimated $25.9K added.
- The largest Grace Therapeutics seller in Q3 2017 was Renaissance Technologies, an estimated $7.48K sold.
Based on aggregated 13F filings for Q3 2017.